Quest buys SmithKline's laboratory business for $1.3 billion - Update
This article was originally published in Clinica
Executive Summary
SmithKline Beecham has sold its $1.6 billion turnover clinical laboratories business to Quest Diagnostics for $1.3 billion in cash and stock. The move is part of SmithKline's divestiture of two parts of its healthcare business. It has also sold Diversified Pharmaceuticals Services for $700 million.